Clinical Trials Logo

Clinical Trial, Phase I clinical trials

View clinical trials related to Clinical Trial, Phase I.

Filter by:
  • None
  • Page 1

NCT ID: NCT04375267 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

LuPARP
Start date: April 23, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent survival of the tumour cells, making them more sensitive to β-emission and increase the probability of tumour cell death.

NCT ID: NCT03484585 Completed - Pharmacokinetics Clinical Trials

Rogaratinib (BAY1163877) Human Mass Balance Study

Start date: April 6, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 200 mg dose of [14C]rogaratinib given as a solution. For further clinical development, human mass balance data are required to elucidate the absorption, distribution, metabolism, and excretion (ADME) of rogaratinib.

NCT ID: NCT03402438 Completed - Clinical trials for Clinical Trial, Phase I

Renal Impairment Study

Start date: February 12, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate the pharmacokinetics of BAY1142524 in subjects with mild to severe renal impairment compared to age; weight, and gender-matched healthy subjects.

NCT ID: NCT03210246 Completed - Clinical trials for Clinical Trial ,Phase I

Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)

Start date: July 17, 2017
Phase: Phase 1
Study type: Interventional

This study will be performed as a multi-center, randomized, double-blind study in 60 healthy women (2 groups of 30 women) to investigate ovarian activity during simultaneous intake of a COC (containing the estrogen EE and the progestin LNG) and the progesterone receptor modulator (PRM) vilaprisan.

NCT ID: NCT02456129 Completed - Clinical trials for Clinical Trial, Phase I

Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan

Start date: July 2015
Phase: Phase 1
Study type: Interventional

This is a study in postmenopausal women to investigate the Drug-drug interaction (DDI) between itraconazole(ITZ) and orally administered vilaprisan; absolute bioavailability using intravenous microtracer dose of [14C]vilaprisan.

NCT ID: NCT02262663 Completed - Clinical trials for Clinical Trial, Phase I

Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan

Start date: October 2014
Phase: Phase 1
Study type: Interventional

This is a study in healthy women of reproductive age to investigate the pharmacodynamics (mainly ovarian activity), pharmacokinetics and safety of vilaprisan after daily oral administration of 4 different doses over 84 days, using a randomized, parallel-group, multicenter design.